Aytu BioPharma, Inc. (AYTU) |
| 2.18 -0.07 (-3.11%) 07-13 16:00 |
| Open: | 2.24 |
| High: | 2.24 |
| Low: | 2.18 |
| Volume: | 18,149 |
| Market Cap: | 18(M) |
| PE Ratio: | -1.14 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 2.35 |
| Resistance 1: | 2.25 |
| Pivot price: | 2.20 |
| Support 1: | 2.08 |
| Support 2: | 1.73 |
| 52w High: | 3.07 |
| 52w Low: | 1.65 |
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
| EPS | -4.610 |
| Book Value | 3.270 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.417 |
| Profit Margin (%) | -60.17 |
| Operating Margin (%) | -32.74 |
| Return on Assets (ttm) | -3.7 |
| Return on Equity (ttm) | -97.4 |
Wed, 08 Jul 2026
AYTU Q2 2026 Earnings: EPS Miss Slightly Wider Than Expected; Stock Rises 2.74% Amid Strategic Review - Earnings Beat Streak - dars.gov.et
Fri, 26 Jun 2026
Aytu BioPharma, Inc. Actuals & Estimates (NASDAQ:AYTU) - TradingView
Fri, 26 Jun 2026
AYTU Forecast — Price Target — Prediction for 2027 - TradingView
Thu, 25 Jun 2026
Aytu BioPharma Ends Metadate CD License With Lannett; Sell-Through Allowed After Mutual Termination - TradingView
Fri, 05 Jun 2026
Aytu BioPharma Inc. (AYTU) Gains 3.3% as Shares Approach Resistance at $2.30 - Price Target - DonanımHaber
Tue, 19 May 2026
Earnings call transcript: Aytu BioPharma Q3 2026 reveals earnings miss - Investing.com
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |